RXSIGHT INC (RXST) Stock Fundamental Analysis

NASDAQ:RXST • US78349D1072

8.61 USD
+0.57 (+7.09%)
At close: Feb 17, 2026
8.61 USD
0 (0%)
After Hours: 2/17/2026, 8:00:02 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

RXST gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 185 industry peers in the Health Care Equipment & Supplies industry. RXST scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. While showing a medium growth rate, RXST is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • RXST had negative earnings in the past year.
  • In the past year RXST has reported a negative cash flow from operations.
  • RXST had negative earnings in 4 of the past 5 years.
  • RXST had a negative operating cash flow in each of the past 5 years.
RXST Yearly Net Income VS EBIT VS OCF VS FCFRXST Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 20M -20M -40M -60M

1.2 Ratios

  • The Return On Assets of RXST (-11.58%) is comparable to the rest of the industry.
  • With a decent Return On Equity value of -12.95%, RXST is doing good in the industry, outperforming 65.41% of the companies in the same industry.
Industry RankSector Rank
ROA -11.58%
ROE -12.95%
ROIC N/A
ROA(3y)-26.56%
ROA(5y)-20.32%
ROE(3y)-38.11%
ROE(5y)-28.71%
ROIC(3y)N/A
ROIC(5y)N/A
RXST Yearly ROA, ROE, ROICRXST Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 50 -50 100

1.3 Margins

  • The Gross Margin of RXST (74.98%) is better than 86.49% of its industry peers.
  • RXST's Gross Margin has improved in the last couple of years.
  • The Profit Margin and Operating Margin are not available for RXST so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 74.98%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y52.32%
GM growth 5YN/A
RXST Yearly Profit, Operating, Gross MarginsRXST Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 1K -1K -2K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. Health

2.1 Basic Checks

  • RXST does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • RXST has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, RXST has more shares outstanding
  • The debt/assets ratio for RXST has been reduced compared to a year ago.
RXST Yearly Shares OutstandingRXST Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
RXST Yearly Total Debt VS Total AssetsRXST Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

  • RXST has an Altman-Z score of 4.13. This indicates that RXST is financially healthy and has little risk of bankruptcy at the moment.
  • The Altman-Z score of RXST (4.13) is better than 75.14% of its industry peers.
  • RXST has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
  • RXST has a better Debt to Equity ratio (0.00) than 75.68% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 4.13
ROIC/WACCN/A
WACC9.99%
RXST Yearly LT Debt VS Equity VS FCFRXST Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

  • RXST has a Current Ratio of 12.74. This indicates that RXST is financially healthy and has no problem in meeting its short term obligations.
  • With an excellent Current ratio value of 12.74, RXST belongs to the best of the industry, outperforming 96.22% of the companies in the same industry.
  • RXST has a Quick Ratio of 11.44. This indicates that RXST is financially healthy and has no problem in meeting its short term obligations.
  • With an excellent Quick ratio value of 11.44, RXST belongs to the best of the industry, outperforming 95.14% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 12.74
Quick Ratio 11.44
RXST Yearly Current Assets VS Current LiabilitesRXST Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • The earnings per share for RXST have decreased by -6.02% in the last year.
  • RXST shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 10.75%.
  • RXST shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 128.63% yearly.
EPS 1Y (TTM)-6.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-50%
Revenue 1Y (TTM)10.75%
Revenue growth 3Y83.65%
Revenue growth 5Y128.63%
Sales Q2Q%-14.09%

3.2 Future

  • RXST is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 18.71% yearly.
  • The Revenue is expected to grow by 3.37% on average over the next years.
EPS Next Y-50.51%
EPS Next 2Y-25.24%
EPS Next 3Y-13.79%
EPS Next 5Y18.71%
Revenue Next Year-6%
Revenue Next 2Y-1.66%
Revenue Next 3Y2.1%
Revenue Next 5Y3.37%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
RXST Yearly Revenue VS EstimatesRXST Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 50M 100M 150M
RXST Yearly EPS VS EstimatesRXST Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 -0.5 -1 -1.5 -2 -2.5

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for RXST. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RXST. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RXST Price Earnings VS Forward Price EarningsRXST Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RXST Per share dataRXST EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

  • A cheap valuation may be justified as RXST's earnings are expected to decrease with -13.79% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-25.24%
EPS Next 3Y-13.79%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • RXST does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

RXSIGHT INC

NASDAQ:RXST (2/17/2026, 8:00:02 PM)

After market: 8.61 0 (0%)

8.61

+0.57 (+7.09%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-05
Earnings (Next)02-25
Inst Owners81.29%
Inst Owner Change3.52%
Ins Owners5.5%
Ins Owner Change0.73%
Market Cap354.04M
Revenue(TTM)142.09M
Net Income(TTM)-35.73M
Analysts52.5
Price Target10.6 (23.11%)
Short Float %10.76%
Short Ratio4.23
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)10.6%
Min EPS beat(2)-16.68%
Max EPS beat(2)37.88%
EPS beat(4)3
Avg EPS beat(4)10.37%
Min EPS beat(4)-16.68%
Max EPS beat(4)37.88%
EPS beat(8)7
Avg EPS beat(8)18.14%
EPS beat(12)11
Avg EPS beat(12)20.21%
EPS beat(16)15
Avg EPS beat(16)18.27%
Revenue beat(2)1
Avg Revenue beat(2)5.69%
Min Revenue beat(2)-6.3%
Max Revenue beat(2)17.67%
Revenue beat(4)1
Avg Revenue beat(4)1.66%
Min Revenue beat(4)-6.3%
Max Revenue beat(4)17.67%
Revenue beat(8)4
Avg Revenue beat(8)2.11%
Revenue beat(12)8
Avg Revenue beat(12)3.07%
Revenue beat(16)12
Avg Revenue beat(16)5.11%
PT rev (1m)0.54%
PT rev (3m)15.43%
EPS NQ rev (1m)4.27%
EPS NQ rev (3m)4.61%
EPS NY rev (1m)0.33%
EPS NY rev (3m)13.62%
Revenue NQ rev (1m)7.36%
Revenue NQ rev (3m)9.48%
Revenue NY rev (1m)1.47%
Revenue NY rev (3m)4.86%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.49
P/FCF N/A
P/OCF N/A
P/B 1.28
P/tB 1.28
EV/EBITDA N/A
EPS(TTM)-0.88
EYN/A
EPS(NY)-1.13
Fwd EYN/A
FCF(TTM)-0.54
FCFYN/A
OCF(TTM)-0.45
OCFYN/A
SpS3.46
BVpS6.71
TBVpS6.71
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -11.58%
ROE -12.95%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 74.98%
FCFM N/A
ROA(3y)-26.56%
ROA(5y)-20.32%
ROE(3y)-38.11%
ROE(5y)-28.71%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y52.32%
GM growth 5YN/A
F-Score5
Asset Turnover0.46
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 120.49%
Cap/Sales 2.49%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 12.74
Quick Ratio 11.44
Altman-Z 4.13
F-Score5
WACC9.99%
ROIC/WACCN/A
Cap/Depr(3y)107.67%
Cap/Depr(5y)87%
Cap/Sales(3y)4.72%
Cap/Sales(5y)8.01%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-6.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-50%
EPS Next Y-50.51%
EPS Next 2Y-25.24%
EPS Next 3Y-13.79%
EPS Next 5Y18.71%
Revenue 1Y (TTM)10.75%
Revenue growth 3Y83.65%
Revenue growth 5Y128.63%
Sales Q2Q%-14.09%
Revenue Next Year-6%
Revenue Next 2Y-1.66%
Revenue Next 3Y2.1%
Revenue Next 5Y3.37%
EBIT growth 1Y-16.38%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-32.57%
EBIT Next 3Y-2.61%
EBIT Next 5YN/A
FCF growth 1Y56.24%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y60.43%
OCF growth 3YN/A
OCF growth 5YN/A

RXSIGHT INC / RXST FAQ

What is the ChartMill fundamental rating of RXSIGHT INC (RXST) stock?

ChartMill assigns a fundamental rating of 3 / 10 to RXST.


What is the valuation status for RXST stock?

ChartMill assigns a valuation rating of 0 / 10 to RXSIGHT INC (RXST). This can be considered as Overvalued.


Can you provide the profitability details for RXSIGHT INC?

RXSIGHT INC (RXST) has a profitability rating of 2 / 10.


How financially healthy is RXSIGHT INC?

The financial health rating of RXSIGHT INC (RXST) is 6 / 10.


What is the earnings growth outlook for RXSIGHT INC?

The Earnings per Share (EPS) of RXSIGHT INC (RXST) is expected to decline by -50.51% in the next year.